BioXcel touts healthy volunteer data for neuro therapy; Ionis, Chinook partner on rare kidney disease
BioXcel Therapeutics reported some new healthy volunteer data that it’s touting as positive.
The biotech said in a press release Tuesday that its experimental BXCL501 therapy as an adjunct for major depressive disorder proved safe and tolerable in a Phase Ib multiple-ascending dose trial, results that allow researchers to select a dose for Phase II. The maximum tolerated dose was not attained, CMO Robert Risinger said in a statement.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.